Activation of coagulation in acute cardioembolic stroke.

The hematologic disorders in patients with acute cardioembolic stroke are not fully understood, and no reliable measures are available to identify patients at high risk for recurrent embolism. We analyzed coagulation and fibrinolytic functions in 22 patients with cardiogenic cerebral embolism less than or equal to 24 hours after onset and in 25 age-matched controls. The levels of antithrombin III, protein C, and alpha 2-plasmin inhibitor were significantly lower in the patients than in the controls (p less than 0.001, 0.02, and 0.05, respectively). In contrast, the plasma concentrations of thrombin-antithrombin III complex and crosslinked D-dimer were markedly higher in the patients than in the controls (p less than 0.01 and 0.001, respectively). At the time of admission, the plasma concentrations of thrombin-antithrombin III complex and crosslinked D-dimer in the eight patients at high risk for recurrent embolization (one with prodromal embolism, three with intracardiac thrombi, and four with recurrent embolization) were 2.8 and 3.5 times, respectively, higher than those in the 14 patients without recurrence or thrombus formation. The lowest concentration of crosslinked D-dimer in the eight patients at high risk for recurrent embolization was 600 ng/ml on admission. Our results suggest that patients with acute cardioembolic stroke have various degrees of consumption coagulopathy and that the plasma concentrations of thrombin-antithrombin III complex and crosslinked D-dimer can be useful indicators of those who are prone to recurrent embolization during this stage.

[1]  W. Kisiel,et al.  Hypercoagulability in acute ischemic stroke: analysis of the extrinsic coagulation reactions in plasma by a highly sensitive automated method. , 1990, Thrombosis research.

[2]  K. Minematsu,et al.  [Differences in CT findings between embolic and thrombotic cerebral artery occlusion of the internal carotid arterial system]. , 1989, Rinsho shinkeigaku = Clinical neurology.

[3]  W. Feinberg,et al.  Hemostatic markers in acute stroke. , 1989, Stroke.

[4]  J. M. Carr,et al.  Diagnosis of disseminated intravascular coagulation. Role of D-dimer. , 1989, American journal of clinical pathology.

[5]  C. Soria,et al.  Factor VII hyperactivity in acute myocardial thrombosis. A relation to the coagulation activation. , 1988, Thrombosis research.

[6]  A. Morabito,et al.  Hypercoagulability in acute stroke , 1987, Neurology.

[7]  A. Jaffe,et al.  Relationship between elevated plasma levels of crosslinked fibrin degradation products (XL-FDP) and the clinical presentation of patients with myocardial infarction. , 1987, Thrombosis research.

[8]  T. Terao,et al.  Preeclampsia as chronic disseminated intravascular coagulation. Study of two parameters: thrombin-antithrombin III complex and D-dimers. , 1987, Gynecologic and obstetric investigation.

[9]  C. Hickton,et al.  A functional assay of protein C in human plasma. , 1986, Thrombosis research.

[10]  K. Minematsu,et al.  Early recurrence of embolic stroke , 1986 .

[11]  H. Pelzer,et al.  Enzyme immunoassay for determination of human thrombin/antithrombin III complex , 1986 .

[12]  B. Coull,et al.  Enhanced in vivo platelet activation in subtypes of ischemic stroke. , 1985, Stroke.

[13]  R. Laureno,et al.  Anticoagulant-Related Hemorrhage in Acute Cerebral Embolism , 1984, Stroke.

[14]  Kaname. Nakamura,et al.  Selective determination of α2-plasmin inhibitor activity in plasma using chromogenic substrate , 1984 .

[15]  Y. Fukuda,et al.  The incidence of thromboembolism and the hemocoagulative background in patients with rheumatic heart disease. , 1984, Japanese circulation journal.

[16]  L. Wilkins Immediate anticoagulation of embolic stroke: a randomized trial. Cerebral Embolism Study Group. , 1983, Stroke.

[17]  D. Rylatt,et al.  Measurement of Crosslinked Fibrin Degradation Products – An Immunoassay Using Monoclonal Antibodies , 1983, Thrombosis and Haemostasis.

[18]  H. Tomoda,et al.  Evaluation of intracardiac thrombus with computed tomography. , 1983, The American journal of cardiology.

[19]  Richard L. Roller Recurrent embolic cerebral infarction and anticoagulation , 1982, Neurology.

[20]  R. Koller Recurrent embolic cerebral infarction and anticoagulation. , 1982, Neurology.

[21]  A. Bloom,et al.  Platelet and Coagulation Function in Patients with Abnormal Cardiac Valves Treated with Sulphinpyrazone , 1981, Thrombosis and Haemostasis.

[22]  G. Claeson,et al.  Methods for the Determination of Plasmin, Antiplasmin and Plasminogen by Means of the Substrate S-2251 , 1977, Thrombosis and Haemostasis.

[23]  O. Odegård,et al.  Antithrombin (heparin cofactor) assay with "new" chromogenic substrates (S-2238 and Chromozym TH). , 1977, Thrombosis research.

[24]  P. Steele,et al.  Platelet survival in patients with rheumatic heart disease. , 1974, The New England journal of medicine.